CRISPR/Cas9 gene editors Intellia Therapeutics (NTLA +4.6%) and Editas Medicine (EDIT +8.4%) are enjoying a spike in demand after Vertex Pharmaceuticals in-licensed the technology from CRISPR Therapeutics (CRSP+15%) to develop gene therapies for Duchenne muscular dystrophy and myotonic dystrophy Type 1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.